Indefinite Delivery Contract 75D30126D20726

Seqirus USA Inc. has been awarded a multiple-award Indefinite Delivery Contract valued at $167.1 million by the Centers for Disease Control and Prevention (CDC) for the procurement of pediatric influenza vaccines targeting children ages 0-18. The contract, awarded December 31, 2025, with an ultimate completion date of February 28, 2027, supports the Vaccine for Children (VFC) program, which was established under the Omnibus Budget Reconciliation Act of 1993 to provide vaccines to Medicaid-eligible children, uninsured children, American Indian/Alaska Native children, and children whose private insurance does not cover vaccine costs. As the primary product deliverable, Seqirus will supply various pediatric influenza vaccine formulations with a minimum shelf life extending through June 30, 2027, with anticipated delivery commencing in Fall 2026 to CDC centralized distribution locations in Olive Branch, Mississippi and Clermont, Kentucky. The contract structure operates as an Indefinite Delivery/Indefinite Quantity agreement with firm-fixed price delivery orders, establishing a combined ceiling across all awarded contracts of either 6 million doses or $710 million (whichever is reached first), with individual contract minimums of 100 doses and maximums of 30 million doses per order.

This procurement was solicited through a competitive, non-set-aside process announced August 14, 2025, with proposals due August 28, 2025, under solicitation number 75D30125R73357. The CDC evaluated competing proposals based on technical compliance with Federal Drug Administration licensing requirements, pricing competitiveness, and demonstrated past performance capabilities. The solicitation incorporated small business subcontracting goals totaling 12.17% small business participation, with additional targets for disadvantaged, HUBZone, women-owned, and service-disabled veteran-owned small business categories. Seqirus USA Inc., a foreign-owned biotechnology company headquartered in Summit, New Jersey, and registered as a federal contractor since 2008, was selected as one of the multiple award recipients based on its established track record as a critical supplier of influenza vaccines across various federal healthcare systems and agencies, including the Department of Veterans Affairs, Department of Defense, and Indian Health Service.